Concomitant LATE‐NC in Alzheimer's disease is not associated with increased tau or amyloid‐β pathological burden

The presence of Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is not associated with an increase in the burden of early or late tau or Aβ pathology in Alzheimer's disease. LATE‐NC is associated with a lower final MMSE score independent of tau pathology....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropathology and applied neurobiology 2020-12, Vol.46 (7), p.722-734
Hauptverfasser: McAleese, K. E., Walker, L., Erskine, D., Johnson, M., Koss, D., Thomas, A. J., Attems, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 734
container_issue 7
container_start_page 722
container_title Neuropathology and applied neurobiology
container_volume 46
creator McAleese, K. E.
Walker, L.
Erskine, D.
Johnson, M.
Koss, D.
Thomas, A. J.
Attems, J.
description The presence of Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is not associated with an increase in the burden of early or late tau or Aβ pathology in Alzheimer's disease. LATE‐NC is associated with a lower final MMSE score independent of tau pathology. Aims Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is present in approximately 50% of Alzheimer's disease (AD) cases and is associated with accelerated cognitive decline. Studies indicate a potential synergistic relationship between LATE‐NC and hyperphosphorylated tau. It is unknown if LATE‐NC is an independent driver of cognitive impairment or exerts its influence through synergistic relationships with tau. This cliniconeuropathological study investigated the impact of LATE‐NC on quantified measures of AD‐associated pathology and its impact on clinical measures. Methods A total of 61 AD cases underwent neuropathological assessment for LATE‐NC and quantitative assessment [area covered by immunoreactivity (IR)] for early conformational tau (MC‐1), late‐stage hyperphosphorylated tau (AT8) and amyloid‐β in the amygdala and five neocortical regions. Clinical measures included age of disease onset, final Mini‐Mental State Examination (MMSE) score and rate of cognitive decline. Results LATE‐NC was present in 41 AD cases (AD/LATE‐NC; 67.2%). No significant differences in MC‐1‐IR, AT8‐IR or 4G8‐IR were observed in any region between AD/LATE‐NC and AD without LATE‐NC, indicating no accelerated aggregation or hyperphosphorylation of tau proteins in the AD/LATE‐NC cases. Final MMSE was significantly lower in AD/LATE‐NC cases and was significantly associated with LATE‐NC score even when controlled for the presence of both MC‐1‐IR and AT8‐IR (P = 0.009). Conclusion The presence of LATE‐NC in AD is not associated with an increase in the burden of early or late tau or Aβ pathology. LATE‐NC is associated with a lower final MMSE score independent of tau pathology.
doi_str_mv 10.1111/nan.12664
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2440899882</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2440899882</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3884-48bdbf393cb67e4c727ec5b01c8649b9c03a4851db5fdd4ab690ed75e20be7d63</originalsourceid><addsrcrecordid>eNp10T1uFDEUB3ALBZFNoOACkaUUhGISe-zx2OVqlQ-k1dKEeuSPt6yjGXtjzyjaVByBs3CQHIKT4LCBAgk3r_BPfz29P0LvKTmn5V0EHc5pLQR_hWaUiaaqlSIHaEYYaSoquThERznfEUKaVqg36JDVUglF2QxNixhsHPyow4iX89vLn9--rxbYBzzvHzfgB0gfMnY-g86AfcYhjljnHK3XIzj84MdN0TY9_zs86gnHhPWw66N3JevpB97qcRP7-NVb3WMzJQfhLXq91n2Gdy_zGH25urxd3FTLz9efFvNlZZmUvOLSOLNmilkjWuC2rVuwjSHUSsGVUZYwzWVDnWnWznFthCLg2gZqYqB1gh2js33uNsX7CfLYDT5b6HsdIE65qzknUikp60JP_6F3cUqhbFeU4G3DVM2L-rhXNsWcE6y7bfKDTruOku65i6500f3uotiTl8TJDOD-yj_HL-BiDx58D7v_J3Wr-Wof-QvsupY3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2464753924</pqid></control><display><type>article</type><title>Concomitant LATE‐NC in Alzheimer's disease is not associated with increased tau or amyloid‐β pathological burden</title><source>Wiley Online Library All Journals</source><creator>McAleese, K. E. ; Walker, L. ; Erskine, D. ; Johnson, M. ; Koss, D. ; Thomas, A. J. ; Attems, J.</creator><creatorcontrib>McAleese, K. E. ; Walker, L. ; Erskine, D. ; Johnson, M. ; Koss, D. ; Thomas, A. J. ; Attems, J.</creatorcontrib><description>The presence of Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is not associated with an increase in the burden of early or late tau or Aβ pathology in Alzheimer's disease. LATE‐NC is associated with a lower final MMSE score independent of tau pathology. Aims Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is present in approximately 50% of Alzheimer's disease (AD) cases and is associated with accelerated cognitive decline. Studies indicate a potential synergistic relationship between LATE‐NC and hyperphosphorylated tau. It is unknown if LATE‐NC is an independent driver of cognitive impairment or exerts its influence through synergistic relationships with tau. This cliniconeuropathological study investigated the impact of LATE‐NC on quantified measures of AD‐associated pathology and its impact on clinical measures. Methods A total of 61 AD cases underwent neuropathological assessment for LATE‐NC and quantitative assessment [area covered by immunoreactivity (IR)] for early conformational tau (MC‐1), late‐stage hyperphosphorylated tau (AT8) and amyloid‐β in the amygdala and five neocortical regions. Clinical measures included age of disease onset, final Mini‐Mental State Examination (MMSE) score and rate of cognitive decline. Results LATE‐NC was present in 41 AD cases (AD/LATE‐NC; 67.2%). No significant differences in MC‐1‐IR, AT8‐IR or 4G8‐IR were observed in any region between AD/LATE‐NC and AD without LATE‐NC, indicating no accelerated aggregation or hyperphosphorylation of tau proteins in the AD/LATE‐NC cases. Final MMSE was significantly lower in AD/LATE‐NC cases and was significantly associated with LATE‐NC score even when controlled for the presence of both MC‐1‐IR and AT8‐IR (P = 0.009). Conclusion The presence of LATE‐NC in AD is not associated with an increase in the burden of early or late tau or Aβ pathology. LATE‐NC is associated with a lower final MMSE score independent of tau pathology.</description><identifier>ISSN: 0305-1846</identifier><identifier>EISSN: 1365-2990</identifier><identifier>DOI: 10.1111/nan.12664</identifier><identifier>PMID: 32896913</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Alzheimer's disease ; Amygdala ; Cognitive ability ; Encephalopathy ; Immunoreactivity ; LATE‐NC ; Neurodegenerative diseases ; Neuropathology ; Pathology ; Phosphorylation ; tau pathology ; Tau protein ; TDP‐43</subject><ispartof>Neuropathology and applied neurobiology, 2020-12, Vol.46 (7), p.722-734</ispartof><rights>2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society</rights><rights>2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3884-48bdbf393cb67e4c727ec5b01c8649b9c03a4851db5fdd4ab690ed75e20be7d63</citedby><cites>FETCH-LOGICAL-c3884-48bdbf393cb67e4c727ec5b01c8649b9c03a4851db5fdd4ab690ed75e20be7d63</cites><orcidid>0000-0002-1752-5343 ; 0000-0002-0212-9823</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fnan.12664$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fnan.12664$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32896913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McAleese, K. E.</creatorcontrib><creatorcontrib>Walker, L.</creatorcontrib><creatorcontrib>Erskine, D.</creatorcontrib><creatorcontrib>Johnson, M.</creatorcontrib><creatorcontrib>Koss, D.</creatorcontrib><creatorcontrib>Thomas, A. J.</creatorcontrib><creatorcontrib>Attems, J.</creatorcontrib><title>Concomitant LATE‐NC in Alzheimer's disease is not associated with increased tau or amyloid‐β pathological burden</title><title>Neuropathology and applied neurobiology</title><addtitle>Neuropathol Appl Neurobiol</addtitle><description>The presence of Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is not associated with an increase in the burden of early or late tau or Aβ pathology in Alzheimer's disease. LATE‐NC is associated with a lower final MMSE score independent of tau pathology. Aims Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is present in approximately 50% of Alzheimer's disease (AD) cases and is associated with accelerated cognitive decline. Studies indicate a potential synergistic relationship between LATE‐NC and hyperphosphorylated tau. It is unknown if LATE‐NC is an independent driver of cognitive impairment or exerts its influence through synergistic relationships with tau. This cliniconeuropathological study investigated the impact of LATE‐NC on quantified measures of AD‐associated pathology and its impact on clinical measures. Methods A total of 61 AD cases underwent neuropathological assessment for LATE‐NC and quantitative assessment [area covered by immunoreactivity (IR)] for early conformational tau (MC‐1), late‐stage hyperphosphorylated tau (AT8) and amyloid‐β in the amygdala and five neocortical regions. Clinical measures included age of disease onset, final Mini‐Mental State Examination (MMSE) score and rate of cognitive decline. Results LATE‐NC was present in 41 AD cases (AD/LATE‐NC; 67.2%). No significant differences in MC‐1‐IR, AT8‐IR or 4G8‐IR were observed in any region between AD/LATE‐NC and AD without LATE‐NC, indicating no accelerated aggregation or hyperphosphorylation of tau proteins in the AD/LATE‐NC cases. Final MMSE was significantly lower in AD/LATE‐NC cases and was significantly associated with LATE‐NC score even when controlled for the presence of both MC‐1‐IR and AT8‐IR (P = 0.009). Conclusion The presence of LATE‐NC in AD is not associated with an increase in the burden of early or late tau or Aβ pathology. LATE‐NC is associated with a lower final MMSE score independent of tau pathology.</description><subject>Alzheimer's disease</subject><subject>Amygdala</subject><subject>Cognitive ability</subject><subject>Encephalopathy</subject><subject>Immunoreactivity</subject><subject>LATE‐NC</subject><subject>Neurodegenerative diseases</subject><subject>Neuropathology</subject><subject>Pathology</subject><subject>Phosphorylation</subject><subject>tau pathology</subject><subject>Tau protein</subject><subject>TDP‐43</subject><issn>0305-1846</issn><issn>1365-2990</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp10T1uFDEUB3ALBZFNoOACkaUUhGISe-zx2OVqlQ-k1dKEeuSPt6yjGXtjzyjaVByBs3CQHIKT4LCBAgk3r_BPfz29P0LvKTmn5V0EHc5pLQR_hWaUiaaqlSIHaEYYaSoquThERznfEUKaVqg36JDVUglF2QxNixhsHPyow4iX89vLn9--rxbYBzzvHzfgB0gfMnY-g86AfcYhjljnHK3XIzj84MdN0TY9_zs86gnHhPWw66N3JevpB97qcRP7-NVb3WMzJQfhLXq91n2Gdy_zGH25urxd3FTLz9efFvNlZZmUvOLSOLNmilkjWuC2rVuwjSHUSsGVUZYwzWVDnWnWznFthCLg2gZqYqB1gh2js33uNsX7CfLYDT5b6HsdIE65qzknUikp60JP_6F3cUqhbFeU4G3DVM2L-rhXNsWcE6y7bfKDTruOku65i6500f3uotiTl8TJDOD-yj_HL-BiDx58D7v_J3Wr-Wof-QvsupY3</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>McAleese, K. E.</creator><creator>Walker, L.</creator><creator>Erskine, D.</creator><creator>Johnson, M.</creator><creator>Koss, D.</creator><creator>Thomas, A. J.</creator><creator>Attems, J.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1752-5343</orcidid><orcidid>https://orcid.org/0000-0002-0212-9823</orcidid></search><sort><creationdate>202012</creationdate><title>Concomitant LATE‐NC in Alzheimer's disease is not associated with increased tau or amyloid‐β pathological burden</title><author>McAleese, K. E. ; Walker, L. ; Erskine, D. ; Johnson, M. ; Koss, D. ; Thomas, A. J. ; Attems, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3884-48bdbf393cb67e4c727ec5b01c8649b9c03a4851db5fdd4ab690ed75e20be7d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alzheimer's disease</topic><topic>Amygdala</topic><topic>Cognitive ability</topic><topic>Encephalopathy</topic><topic>Immunoreactivity</topic><topic>LATE‐NC</topic><topic>Neurodegenerative diseases</topic><topic>Neuropathology</topic><topic>Pathology</topic><topic>Phosphorylation</topic><topic>tau pathology</topic><topic>Tau protein</topic><topic>TDP‐43</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McAleese, K. E.</creatorcontrib><creatorcontrib>Walker, L.</creatorcontrib><creatorcontrib>Erskine, D.</creatorcontrib><creatorcontrib>Johnson, M.</creatorcontrib><creatorcontrib>Koss, D.</creatorcontrib><creatorcontrib>Thomas, A. J.</creatorcontrib><creatorcontrib>Attems, J.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropathology and applied neurobiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McAleese, K. E.</au><au>Walker, L.</au><au>Erskine, D.</au><au>Johnson, M.</au><au>Koss, D.</au><au>Thomas, A. J.</au><au>Attems, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Concomitant LATE‐NC in Alzheimer's disease is not associated with increased tau or amyloid‐β pathological burden</atitle><jtitle>Neuropathology and applied neurobiology</jtitle><addtitle>Neuropathol Appl Neurobiol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>46</volume><issue>7</issue><spage>722</spage><epage>734</epage><pages>722-734</pages><issn>0305-1846</issn><eissn>1365-2990</eissn><abstract>The presence of Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is not associated with an increase in the burden of early or late tau or Aβ pathology in Alzheimer's disease. LATE‐NC is associated with a lower final MMSE score independent of tau pathology. Aims Limbic‐predominant age‐related TDP‐43 encephalopathy neuropathological change (LATE‐NC) is present in approximately 50% of Alzheimer's disease (AD) cases and is associated with accelerated cognitive decline. Studies indicate a potential synergistic relationship between LATE‐NC and hyperphosphorylated tau. It is unknown if LATE‐NC is an independent driver of cognitive impairment or exerts its influence through synergistic relationships with tau. This cliniconeuropathological study investigated the impact of LATE‐NC on quantified measures of AD‐associated pathology and its impact on clinical measures. Methods A total of 61 AD cases underwent neuropathological assessment for LATE‐NC and quantitative assessment [area covered by immunoreactivity (IR)] for early conformational tau (MC‐1), late‐stage hyperphosphorylated tau (AT8) and amyloid‐β in the amygdala and five neocortical regions. Clinical measures included age of disease onset, final Mini‐Mental State Examination (MMSE) score and rate of cognitive decline. Results LATE‐NC was present in 41 AD cases (AD/LATE‐NC; 67.2%). No significant differences in MC‐1‐IR, AT8‐IR or 4G8‐IR were observed in any region between AD/LATE‐NC and AD without LATE‐NC, indicating no accelerated aggregation or hyperphosphorylation of tau proteins in the AD/LATE‐NC cases. Final MMSE was significantly lower in AD/LATE‐NC cases and was significantly associated with LATE‐NC score even when controlled for the presence of both MC‐1‐IR and AT8‐IR (P = 0.009). Conclusion The presence of LATE‐NC in AD is not associated with an increase in the burden of early or late tau or Aβ pathology. LATE‐NC is associated with a lower final MMSE score independent of tau pathology.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32896913</pmid><doi>10.1111/nan.12664</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1752-5343</orcidid><orcidid>https://orcid.org/0000-0002-0212-9823</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-1846
ispartof Neuropathology and applied neurobiology, 2020-12, Vol.46 (7), p.722-734
issn 0305-1846
1365-2990
language eng
recordid cdi_proquest_miscellaneous_2440899882
source Wiley Online Library All Journals
subjects Alzheimer's disease
Amygdala
Cognitive ability
Encephalopathy
Immunoreactivity
LATE‐NC
Neurodegenerative diseases
Neuropathology
Pathology
Phosphorylation
tau pathology
Tau protein
TDP‐43
title Concomitant LATE‐NC in Alzheimer's disease is not associated with increased tau or amyloid‐β pathological burden
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A06%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Concomitant%20LATE%E2%80%90NC%20in%20Alzheimer's%20disease%20is%20not%20associated%20with%20increased%20tau%20or%20amyloid%E2%80%90%CE%B2%20pathological%20burden&rft.jtitle=Neuropathology%20and%20applied%20neurobiology&rft.au=McAleese,%20K.%20E.&rft.date=2020-12&rft.volume=46&rft.issue=7&rft.spage=722&rft.epage=734&rft.pages=722-734&rft.issn=0305-1846&rft.eissn=1365-2990&rft_id=info:doi/10.1111/nan.12664&rft_dat=%3Cproquest_cross%3E2440899882%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2464753924&rft_id=info:pmid/32896913&rfr_iscdi=true